These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19381990)

  • 1. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
    Henderson RJ; Leon CG; Wasan KM
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations.
    Patankar N; Wasan KM
    Pharm Res; 2006 May; 23(5):1020-4. PubMed ID: 16715392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
    Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
    Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
    Gershkovich P; Wasan EK; Lin M; Sivak O; Leon CG; Clement JG; Wasan KM
    J Antimicrob Chemother; 2009 Jul; 64(1):101-8. PubMed ID: 19398459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.
    Sivak O; Lau B; Patankar N; Wasan KM
    Pharm Res; 2004 Dec; 21(12):2336-9. PubMed ID: 15648266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
    Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
    Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interfacial and lipid transfer properties of human phospholipid transfer protein: implications for the transfer mechanism of phospholipids.
    Setälä NL; Holopainen JM; Metso J; Wiedmer SK; Yohannes G; Kinnunen PK; Ehnholm C; Jauhiainen M
    Biochemistry; 2007 Feb; 46(5):1312-9. PubMed ID: 17260960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
    Bellmann R; Egger P; Wiedermann CJ
    Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
    Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
    J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
    Ramos H; Brajtburg J; Marquez V; Cohen BE
    Drugs Exp Clin Res; 1995; 21(6):211-6. PubMed ID: 8907695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma.
    Henderson RJ; Wasan KM; Leon CG
    Lipids Health Dis; 2009 Jul; 8():27. PubMed ID: 19627602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
    Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
    Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
    Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phospholipid transfer protein is present in human tear fluid.
    Jauhiainen M; Setälä NL; Ehnholm C; Metso J; Tervo TM; Eriksson O; Holopainen JM
    Biochemistry; 2005 Jun; 44(22):8111-6. PubMed ID: 15924430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
    Ruijgrok EJ; Vulto AG; Van Etten EW
    J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane.
    Shimizu K; Osada M; Takemoto K; Yamamoto Y; Asai T; Oku N
    J Control Release; 2010 Jan; 141(2):208-15. PubMed ID: 19815038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA.
    Desrumaux C; Athias A; Bessède G; Vergès B; Farnier M; Perségol L; Gambert P; Lagrost L
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):266-75. PubMed ID: 9974406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.